Key Takeaways in the Treatment of Advanced RCC From KCRS 2023

Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.

EP: 1.Overview of First-Line Combination Therapy in Advanced Clear Cell RCC

EP: 2.Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC

EP: 3.Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies

EP: 4.Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC

EP: 5.Selecting Therapy for a Real-World Patient With Clear Cell RCC

EP: 6.Rationale Behind Discontinuing IO Therapy in Clear Cell RCC

EP: 7.Second-Line Treatment Armamentarium in Clear Cell RCC

EP: 8.Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies

EP: 9.Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

EP: 10.Renal Cell Carcinoma: Future Evolutions in Care

EP: 11.Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)

EP: 12.Available Treatment Options for Patients with Advanced RCC

EP: 13.Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC

EP: 14.Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC

EP: 15.Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC

Now Viewing

EP: 16.Key Takeaways in the Treatment of Advanced RCC From KCRS 2023

EP: 17.Future Perspectives in the Treatment of Advanced RCC

Related Videos

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment